Physician profile
Jeff L Thode
NPI 1811969363
$525.51
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.22 · 2020: $18.50 · 2022: $345 · 2023: $82.51 · 2024: $54.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $173.49 | 2022-2024 | |
| Amgen INC. | $58.09 | 2019-2023 | Prolia, Evenity |
| Novo Nordisk INC | $57.90 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.99 | 2023 | Glassia, Gattex |
| Sunovion Pharmaceuticals INC. | $36.60 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.73 | 2022 | |
| Corium, LLC | $28.77 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.03 | 2023 | Keveyis |
| Pfizer INC. | $15.89 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.77 | 2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $14.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.29 | 2024 | Ofev |
| Sanofi-Aventis U.S. LLC | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Thode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.